Author, year
Comparison
Duration Of treatment Phase of study, location
Dosage of HIF-PHI
Baseline Hb(g/dL) (HIF-PHI/Control) Age (HIF-PHI/Control) HIF-PHI group(n) (Male/Female) Control group (n) (Male/Female)
Chen et al.2019[12]
Roxadustat vs Epoetin
26 weeks
Ⅲ, China
Starting dose: 100 mg (45-60 kg) or 120 mg (≥60 kg) TIW
10.40 ± 0.70/10.50 ± 0.70
47.6±11.7/51.0±11.8
204 (126/78)
100 (58/42)
Akizawa et al.2020a[26] Roxadustat vs Darbepoetin 24 weeks Ⅲ, Japan Starting dose: 70 or 100 mg TIW 11.02 ± 0.56/11.01 ± 0.60 64.6±11.7/64.9±10.1 150 (101/49) 151 (107/44)
Provenzano et al.2021[27]
Roxadustat vs Epoetin
52 weeks
Ⅲ, Global
Starting dose: 70 mg (<70 kg) or 100 mg (≥70 kg) TIW
8.43 ± 1.04/8.46 ± 0.96
53.8±14.7/54.3±14.6
522 (309/213)
521 (307/214)
Hou et al.2021[28]
Roxadustat vs. ESAs
24 weeks
Ⅲ, China
Starting dose: 100 mg (45-60 kg) or120 mg (≥60 kg) TIW
9.00 ± 1.40/9.00 ± 1.20
48.0±12.0/48.3±13.0
86 (47/39)
43 (25/18)
Csiky et al.2021[29] Roxadustat vs Daebepotin 52 weeks Ⅲ, Global Starting dose: 20, 50 and 100mg TIW 10.75 ± 0.62/10.78 ± 0.62 61.0±13.8/61.8±13.4 414 (245/169) 420 (235/185)
Charytan et al.2021[30] Roxadustat vs Epoetin 52 weeks Ⅲ, US Starting dose: 70-200mg TIW based on the pre-study ESA dose 10.30 ± 0.66 10.31 ± 0.66 57.6±13.6/58.4±13.3 370 (187/183) 371 (215/156)
Fishbane et al. 2022[16]
Roxadustat vs Epoetin
4 years
Ⅲ, Global
Starting dose: ESAs naive:70mg(45-70kg) or 100 mg (70-160 kg) TIW ESAs users:70-200 mg TIW
10.10 ± 0.80/10.10 ± 0.90
53.5±15.3/54.5±15.0
1051 (625/426)
1055 (626/429)
Singh et al.2021[31] Daprodustat vs Epoetin 21 months Ⅲ, Global Starting dose: 4-12mg q. d. 10.35 ± 0.97/10.39 ± 0.98 57.2±14.3/57.3±14.7 1487 (851/636) 1477 (847/630)
Meadowcroft et al.2019[32] Daprodustat vs rhEPO, ESAs 24 weeks Global Starting dose: 4-12mg q. d. 10.40 ± 0.66/10.60 ± 0.94 59.6±13.3/59.7±18.7 171 (108/63) 39 (26/13)
Akizawa et al. 2020b[33] Daprodustat vs Darbepoetin 52 weeks Ⅲ, Japan Starting dose: 4mg q. d. 10.90 ± 0.80/10.80 ± 0.70 64.0±10.0/64.0±11.0 136 (91/45) 135 (89/46)
Singh et al.2022[34] Daprodustat vs Darbepoetin 52 weeks Ⅲ, Global Starting dose: 1-24mg q. d. 9.50 ± 0.10/9.50 ± 0.10 53.7±14.3/55.8±15.7 157 (96/61) 155 (98/57)
Coyne et al.2022[35]
Daprodustat vs Epoetin
52 weeks
Ⅲ, Global

Starting dose: 2-48mg TIW

10.44 ± 0.83/10.59 ± 0.93
60 (50–69)/56 (46.5–65.5)
270 (149/121)
137 (81/56)
Eckardt et al.2021[2]
Vadadustat vs Darbepoetin
52 weeks
Ⅲ, Global
Starting dose: 300mg q. d. Maintenance dose: 150-600mg q. d.
9.40 ± 1.10/9.20 ± 1.10
56.5±14.8/55.6±14.6
181 (107/74)
188 (113/75)
Eckardt et al.2021[2]
Vadadustat vs Darbepoetin
52 weeks
Ⅲ, Global
Starting dose: 300mg q. d. Maintenance dose: 150-600mg q. d.
10.60 ± 0.90/10.20 ± 0.80
57.9±13.9/58.4±13.8
1777 (990/787)
1777 (1004/773)
Nangaku et al.2021[36]
Vadadustat vs Darbepoetin
52 weeks
Ⅲ, Japan
Starting dose: 300mg q. d. Maintenance dose: 150-600mg q. d.
10.73 ± 0.70/10.73 ± 0.70
66.0±11.3/64.9±11.7
162 (104/58)
161 (109/52)
Macdougall et al.2019[37] Molidustat vs Epoetin 16 weeks Ⅱb, US and Japan Starting dose: 25-150mg 10.50 ± 0.60/10.60 ± 0.50 59.0±13.0/59.0±9.0 157 (91/66) 42 (29/13)
Akizawa et al.2019[38] Molidustat vs Epoetin 52 weeks Ⅱb, Global Starting dose: 15-150mg q. d. 10.40 ± 0.70/10.50 ± 0.50 61.0±12.0/59.0±9.0 57 (33/24) 30 (23/7)
Akizawa et al.2021[40]
Molidustat vs Darbepoetin
52 weeks
Ⅲ, Japan
Starting dose: ESAs naive:75mg q. d. user: 100/125/150mg based on prior ESA dose
10.79±0.65/10.87±0.64
66.2±10.3/64.8±10.6
153(91/62)
76(49/27)
Akizawa et al.2021[39] Enarodustat vs Darbepoetin 24 weeks Ⅲ, Japan Starting dose: 4mg q. d. 10.79 ± 0.65/10.87 ± 0.70 63.2±10.8/64.8±10.3 86 (61/25) 86 (61/25)
Gang et al.2022[41] Desidustat vs Epoetin 24 weeks Ⅲ, India Starting dose: 100mg TIW 9.61±0.99/9.55±1.37 51.0±14.0/51.0±13.5 196(135/61) 196(134/62)